- Home
- ACIU vs CRVS Comparison
ACIU vs CRVS Comparison
Compare ACIU & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- CRVS
- Stock Information
- Founded
- ACIU 2003
- CRVS 2014
- Country
- ACIU Switzerland
- CRVS United States
- Employees
- ACIU N/A
- CRVS N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- ACIU Health Care
- CRVS Health Care
- Exchange
- ACIU Nasdaq
- CRVS Nasdaq
- Market Cap
- ACIU 247.4M
- CRVS 257.0M
- IPO Year
- ACIU 2016
- CRVS 2016
- Fundamental
- Price
- ACIU $1.77
- CRVS $2.99
- Analyst Decision
- ACIU Strong Buy
- CRVS Strong Buy
- Analyst Count
- ACIU 2
- CRVS 5
- Target Price
- ACIU $12.00
- CRVS $12.63
- AVG Volume (30 Days)
- ACIU 185.3K
- CRVS 715.8K
- Earning Date
- ACIU 05-12-2025
- CRVS 05-05-2025
- Dividend Yield
- ACIU N/A
- CRVS N/A
- EPS Growth
- ACIU N/A
- CRVS N/A
- EPS
- ACIU N/A
- CRVS N/A
- Revenue
- ACIU $30,136,397.00
- CRVS N/A
- Revenue This Year
- ACIU N/A
- CRVS N/A
- Revenue Next Year
- ACIU $680.74
- CRVS N/A
- P/E Ratio
- ACIU N/A
- CRVS N/A
- Revenue Growth
- ACIU 84.51
- CRVS N/A
- 52 Week Low
- ACIU $1.77
- CRVS $1.30
- 52 Week High
- ACIU $4.98
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- ACIU 25.49
- CRVS 26.38
- Support Level
- ACIU $1.77
- CRVS $3.06
- Resistance Level
- ACIU $2.05
- CRVS $3.31
- Average True Range (ATR)
- ACIU 0.12
- CRVS 0.36
- MACD
- ACIU -0.02
- CRVS -0.10
- Stochastic Oscillator
- ACIU 0.00
- CRVS 1.11
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).